UroGen Reports Strong Phase 3 UGN-103 Bladder Cancer Data
PRINCETON, N.J., May 15, 2026 UroGen Pharma Ltd. announced positive six-month results from the ongoing Phase 3 UTOPIA trial,...
ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
PRINCETON, N.J., May 15, 2026 UroGen Pharma Ltd. announced positive six-month results from the ongoing Phase 3 UTOPIA trial,...
PRINCETON, N.J., December 5, 2025 — UroGen Pharma Ltd. has announced the issuance of inducement restricted stock units (RSUs)...
